project: cardiodx

CardioDX logo

Connect with a Sales Specialist


Press Releases

CardioDx Announces Presentations at the American College of Cardiology 2012 Scientific Sessions

PALO ALTO, Calif. – March 19, 2012 – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that data related to the company’s Corus® CAD gene expression test will be presented at the American College of Cardiology’s (ACC’s) 61st Annual Scientific Sessions & Expo taking place March 24-27 in Chicago.

Corus CAD is a decision-making tool that, with a simple blood draw, can help primary care clinicians and cardiologists exclude obstructive coronary artery disease as the cause of a stable non-diabetic patient's symptoms. The test has now been used to assess the presence of obstructive coronary artery disease in more than 25,000 U.S. patients.

Clinical and scientific presentations featuring Corus CAD data at the meeting include:

  • “The Diagnostic Yield of Coronary Angiography Remains Low, Despite Prior Myocardial Perfusion Imaging Testing, in Patients With Suspected Obstructive Coronary Artery Disease: Results of the PREDICT Trial” presented by Alexandra Lansky, M.D., of Yale School of Medicine, on Saturday, March 24 from 9:30 a.m. – 12:00 p.m. CT in Hall A, McCormick Place South.
  • “A Previously Validated Peripheral Gene Expression Score is Mostly Determined by Non-Calcified Plaque and Luminal Stenosis as Assessed by Quantitative, 3-Dimensional Measurements by CT Angiography in the Multi-Center, Prospective COMPASS Study” presented by Szilard Voros, M.D. on Sunday, March 25 at 11:30 a.m. CT in Room S403, McCormick Place South.
  • “A Peripheral Blood Gene Expression Score for Coronary Artery Disease in Non-Diabetic Patients Identifies Patients at Low Risk for Major Cardiovascular Events and Interventional Procedures in the Next 12 Months” by Robert S. Schwartz, M.D., of the Minneapolis Heart Institute Foundation, on Sunday, March 25 at 11:48 a.m. CT in Room N230, McCormick Place North.

In addition, Corus CAD will be featured during the following educational symposia:

  • “New Breakthroughs in Cardiovascular Genomics: Approaching the Clinic” presented by Geoffrey Ginsburg, M.D., of Duke University, during the International Society for Cardiovascular Translational Research Symposium on Saturday, March 24 at 8:00 a.m. CT in Room N228, McCormick Place North.
  • “Corus CAD: A New Gene Expression Test to Detect Coronary Artery Disease” presented by Mark Monane, M.D., chief medical officer of CardioDx, during the CV Innovations Educational Forum on Personalized Medicine on Monday, March 26 at 1:50 p.m. CT in Hall A #22097, McCormick Place South.

About Corus CAD
Corus CAD is the first and only clinically validated blood-based test for the assessment of obstructive coronary artery disease. The test involves a routine blood draw conveniently administered in the clinician’s office and does not expose patients to risks of radiation or imaging agent intolerance. It is the first sex-specific test for obstructive coronary artery disease, accounting for critical biological differences between men and women. The test has been honored as a winner of The Wall Street Journal’s prestigious Technology Innovation Awards and one of TIME’s Top Ten Medical Breakthroughs and is a finalist for the 2012 Edison Awards. Findings from the PREDICT validation study of the Corus CAD gene expression test were published in 2010 in the Annals of Internal Medicine, the journal of the American College of Physicians.

The Corus CAD test measures the RNA levels of 23 genes from a whole blood sample. Because these RNA levels are increased or decreased when obstructive coronary artery disease is present, the Corus CAD score indicates the likelihood that an individual patient does not have obstructive coronary artery disease.

Corus CAD is commercially available through an innovative patient sample kit that includes everything needed for blood collection and express delivery to the company’s CLIA-certified Palo Alto, Calif. laboratory. Test results are delivered promptly to the clinician’s office. Corus CAD is currently available in the United States.

For more information please visit

About Gene Expression Testing
Gene expression testing provides valuable tissue and cell-specific information about the molecular mechanisms involved in disease processes, enabling evaluation of an individual patient’s disease state, activity, and/or progression at a given point in time. Unlike genetic tests, which measure genetic variations, mutations, traits and predispositions—factors that are constant over a person’s lifetime— gene expression testing assesses a dynamic process, integrating both genetic predisposition and additional behavioral and environmental influences on current disease state.

About CardioDx
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit


Media Contact:
Nicole Osmer